# NATURES SUNSHINE PRODUCTS INC (NATR)

Informational only - not investment advice.

CIK: 0000275053
SIC: 2834 Pharmaceutical Preparations
SIC breadcrumb: [Manufacturing](/division/D/) > [Chemicals And Allied Products](/major-group/28/) > [SIC 2834 Pharmaceutical Preparations](/industry/2834/)
Latest 10-K filed: 2026-03-10
SEC page: https://www.sec.gov/edgar/browse/?CIK=275053
Filing source: https://www.sec.gov/Archives/edgar/data/275053/000162828026016540/natr-20251231.htm

## At a glance

FY2025 · period end 2025-12-31 · filed 2026-03-10 · accession 0001628280-26-016540 · source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000275053.json

| Metric | Value | FY | Provenance |
| --- | ---: | ---: | --- |
| Revenue | 480,144,000 USD | 2025 | verified |
| Net income | 19,521,000 USD | 2025 | verified |
| Assets | 261,146,000 USD | 2025 | verified |
| Free cash flow | 28,841,000 USD | 2025 | computed |
| Net margin | 4.07% | 2025 | computed |
| Operating margin | 5.15% | 2025 | computed |
| Revenue YoY | +5.67% | 2025 | computed |
| ROE | 12.08% | 2025 | computed |

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

No market price, no rating, no forecast on this site. Not investment advice.

### Peer percentile fingerprint

| Ratio | NATR | Peer median | Percentile | N |
| --- | ---: | ---: | ---: | ---: |
| Net margin | 4.1% | 1.0% | 55 | 107 |
| Operating margin | 5.2% | -1.3% | 54 | 100 |
| Revenue growth | 5.7% | 14.7% | 35 | 127 |
| FCF margin | 6.0% | -14.0% | 62 | 127 |
| ROE | 12.1% | -30.7% | 78 | 171 |
| ROA | 7.5% | -21.8% | 83 | 187 |
| Liabilities / equity | 0.62 | 0.38 | 58 | 173 |
| Current ratio | 2.28 | 4.89 | 18 | 188 |

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC industry 2834 Pharmaceutical Preparations, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

## Selected Fundamentals
| Metric | Value | Unit | FY | Filed |
| --- | ---: | --- | ---: | --- |
| Revenue | 480144000 | USD | 2025 | 2026-03-10 |
| Net income | 19521000 | USD | 2025 | 2026-03-10 |
| Assets | 261146000 | USD | 2025 | 2026-03-10 |

## Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-03-10. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000275053.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

| Metric | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue |  |  | 341,159,000 | 342,029,000 | 364,810,000 | 362,215,000 | 385,205,000 | 444,084,000 | 421,910,000 | 445,320,000 | 454,364,000 | 480,144,000 |
| Net income |  |  |  |  |  |  |  |  | -390,000 | 15,076,000 | 7,696,000 | 19,521,000 |
| Operating income |  |  | 10,039,000 | 1,387,000 | 5,351,000 | 16,125,000 | 21,482,000 | 34,670,000 | 16,258,000 | 18,749,000 | 20,095,000 | 24,743,000 |
| Gross profit |  |  | 250,222,000 | 250,992,000 | 269,119,000 | 268,275,000 | 283,929,000 | 328,617,000 | 299,760,000 | 321,127,000 | 324,688,000 | 347,724,000 |
| Diluted EPS |  |  | 0.11 | -0.69 | -0.04 | 0.34 | 1.07 | 1.42 | -0.02 | 0.77 | 0.40 | 1.06 |
| Operating cash flow |  |  | 3,417,000 | 10,524,000 | 21,833,000 | 8,545,000 | 37,659,000 | 34,608,000 | 710,000 | 41,226,000 | 25,298,000 | 35,321,000 |
| Capital expenditures |  |  | 11,028,000 | 5,501,000 | 4,834,000 | 5,104,000 | 4,905,000 | 6,666,000 | 7,628,000 | 10,478,000 | 10,971,000 | 6,480,000 |
| Share buybacks | 7,455,000 | 6,645,000 | 0.00 | 0.00 |  |  | 0.00 | 7,425,000 | 13,571,000 | 6,397,000 | 8,859,000 | 16,309,000 |
| Assets |  |  | 205,570,000 | 195,195,000 | 193,016,000 | 213,068,000 | 249,498,000 | 258,874,000 | 229,778,000 | 249,773,000 | 240,855,000 | 261,146,000 |
| Liabilities |  |  | 73,172,000 | 75,463,000 | 72,448,000 | 83,632,000 | 92,264,000 | 97,470,000 | 82,731,000 | 90,233,000 | 79,864,000 | 99,593,000 |
| Stockholders' equity |  |  | 132,398,000 | 119,732,000 | 120,568,000 | 129,436,000 | 157,234,000 | 161,404,000 | 147,047,000 | 159,540,000 | 160,991,000 | 161,553,000 |
| Cash and cash equivalents |  |  | 32,284,000 | 42,910,000 | 50,638,000 | 53,629,000 | 92,069,000 | 86,184,000 | 60,032,000 | 82,373,000 | 84,700,000 | 93,891,000 |
| Free cash flow |  |  | -7,611,000 | 5,023,000 | 16,999,000 | 3,441,000 | 32,754,000 | 27,942,000 | -6,918,000 | 30,748,000 | 14,327,000 | 28,841,000 |

### Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

| Metric | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net margin |  |  |  |  |  |  |  |  | -0.09% | 3.39% | 1.69% | 4.07% |
| Operating margin |  |  | 2.94% | 0.41% | 1.47% | 4.45% | 5.58% | 7.81% | 3.85% | 4.21% | 4.42% | 5.15% |
| Return on equity |  |  |  |  |  |  |  |  | -0.27% | 9.45% | 4.78% | 12.08% |
| Return on assets |  |  |  |  |  |  |  |  | -0.17% | 6.04% | 3.20% | 7.48% |
| Liabilities / equity |  |  | 0.55 | 0.63 | 0.60 | 0.65 | 0.59 | 0.60 | 0.56 | 0.57 | 0.50 | 0.62 |
| Current ratio |  |  | 1.50 | 1.91 | 1.60 | 1.94 | 2.21 | 2.15 | 2.28 | 2.16 | 2.44 | 2.28 |

## As-reported value updates

No tracked differences above grepcent's stated thresholds and capped precision rule were found between the earliest XBRL-filed value and the value currently on file for the standardized annual metrics grepcent tracks.


## Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-08-06. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000275053.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

| Quarter | End date | Revenue | Net income | Diluted EPS | Method |
| --- | --- | ---: | ---: | ---: | --- |
| 2022-Q3 | 2022-09-30 |  |  | 0.00 | reported discrete quarter |
| 2023-Q1 | 2023-03-31 |  |  | 0.04 | reported discrete quarter |
| 2023-Q2 | 2023-06-30 |  |  | 0.12 | reported discrete quarter |
| 2023-Q3 | 2023-09-30 | 111,202,000 | 2,832,000 | 0.15 | reported discrete quarter |
| 2023-Q4 | 2023-12-31 | 108,936,000 | 8,962,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2024-Q1 | 2024-03-31 | 110,993,000 | 2,321,000 | 0.12 | reported discrete quarter |
| 2024-Q2 | 2024-06-30 | 110,551,000 | 1,349,000 | 0.07 | reported discrete quarter |
| 2024-Q3 | 2024-09-30 | 114,615,000 | 4,347,000 | 0.23 | reported discrete quarter |
| 2024-Q4 | 2024-12-31 | 118,205,000 | -321,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2025-Q1 | 2025-03-31 | 113,248,000 | 4,747,000 | 0.25 | reported discrete quarter |
| 2025-Q2 | 2025-06-30 | 114,750,000 | 5,333,000 | 0.28 | reported discrete quarter |
| 2025-Q3 | 2025-09-30 | 128,339,000 | 5,334,000 | 0.30 | reported discrete quarter |
| 2025-Q4 | 2025-12-31 | 123,807,000 | 4,107,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2026-Q1 | 2026-03-31 | 122,892,000 | 5,118,000 | 0.29 | reported discrete quarter |
| 2026-Q2 | 2026-06-30 | 116,985,000 | 3,538,000 | 0.19 | reported discrete quarter |

## Filed narrative (10-K & 10-Q)

## Business

Verbatim Item 1 Business section from NATR's latest 10-K: [/company/NATR/business/](/company/NATR/business/).

## Risk Factors

Verbatim Item 1A Risk Factors from NATR's latest 10-K: [/company/NATR/risk-factors/](/company/NATR/risk-factors/).

## Latest quarter (10-Q)

Latest 10-Q source: https://www.sec.gov/Archives/edgar/data/275053/000162828026054468/natr-20260630.htm

Extracted structurally from real Item 2 body heading to real Item 3/4 boundary.
Confidence: high
Filing date: 2026-08-06
Report date: 2026-06-30

Item 2.       MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following Management’s Discussion and Analysis should be read in conjunction with the unaudited condensed consolidated financial statements and notes thereto included in this report, as well as the consolidated financial statements, the notes thereto and management’s discussion and analysis included in our Annual Report on Form 10-K for the year ended December 31, 2025, and our other reports filed since the date of such Form 10-K.

OVERVIEW

We are a global leader in manufacturing and marketing high-quality herbal and nutritional supplements. We are a Utah corporation with our principal place of business in Lehi, Utah, and sell our products directly to consumers and to a sales force of independent consultants who resell our products to consumers.

Our independent consultants market and sell our products to consumers and sponsor other independent consultants who also market our products to consumers. Because a significant amount of revenue is generated through the sales of our independent consultants, our revenue can be impacted by the number and productivity of our independent consultants. We seek to motivate and provide incentives to our independent consultants by offering high quality products, product support, training seminars and financial incentives, among other considerations.

Second Quarter Performance

In the second quarter of 2026, we experienced an increase in our consolidated net sales of 1.9 percent (or 3.8 percent in local currencies) compared to the same period in 2025. Asia net sales increased approximately 0.6 percent (or 5.3 percent in local currencies) compared to the same period in 2025. Europe net sales increased approximately 4.4 percent (or 3.7 percent in local currencies) compared to the same period in 2025. North America net sales increased approximately 2.8 percent (or 2.8 percent in local currencies) compared to the same period in 2025. Latin America and Other net sales decreased approximately 0.5 percent (or 3.7 percent in local currencies) compared to the same period in 2025. The weakening of the local currencies versus the U.S. dollar, primarily in our Asian markets, resulted in an approximate 1.9 percent, or $2.1 million, decrease of our net sales during the quarter.

Cost of sales decreased $1.6 million during the three months ended June 30, 2026, compared to the same period in 2025, and as a percentage of net sales were 26.3 percent and 28.3 percent for the three months ended June 30, 2026 and 2025, respectively. The decrease in cost of sales percentage is primarily due to cost savings initiatives and market mix.

In absolute terms, selling, general and administrative expenses increased $1.2 million during the three months ended June 30, 2026, compared to the same period in 2025, and as a percentage of net sales were 38.4 percent and 38.1 percent for the three months ended June 30, 2026 and 2025, respectively. The increase was primarily related to consultant events and variable selling expenses, partially offset by compensation costs.

As an international business, we have significant sales and costs denominated in currencies other than the U.S. Dollar. We expect foreign markets with functional currencies other than the U.S. Dollar will continue to represent a substantial portion of our overall sales and related operating expenses. Accordingly, changes in foreign currency exchange rates could materially affect sales and costs or the comparability of sales and costs from period to period as a result of translating foreign markets' financial statements into our reporting currency.

21

Table of Contents

Eastern Europe

On February 24, 2022, Russian forces launched significant military action against Ukraine. There continues to be sustained conflict and disruption in the region, which is expected to endure for the foreseeable future. Our consultants in the impacted regions continue to operate their independent businesses, albeit at a reduced level than prior to the start of the conflict. We expect that this will continue to impact our business for the foreseeable future. We will continue monitoring the social, political, regulatory and economic environment in Ukraine and Russia and will consider further actions as appropriate.

More broadly, there could be additional negative impacts to our net sales, earnings and cash flows should the situation escalate beyond its current scope, including, among other potential impacts, economic recessions in certain neighboring countries.

Despite the war in Ukraine, net sales related to Eastern Europe for the three and six months ended June 30, 2026, were $15.1 million and $32.7 million, respectively, compared to $13.5 million and $29.3 million for the same periods in 2025. Operating income related to Eastern Europe for the three and six months ended June 30, 2026 was $1.6 million and $3.6 million, respectively, compared to $1.0 million and $2.4 million for the same periods in 2025. As of June 30, 2026, Eastern Europe had assets of $7.1 million, net of working capital reserves related to inventories.

In November 2024, we began an internal investigation regarding our past compliance with relevant U.S. trade controls and made an initial voluntary self-disclosure of apparent trade controls violations to the U.S. Department of Commerce's Bureau of Industry and Security (“BIS”). In addition, in April 2025 we filed an initial voluntary self-disclosure with the Office of Foreign Asset Control (“OFAC”) relating to the same internal investigation. Following our internal investigation, we filed final voluntary self-disclosures with BIS and OFAC on September 5, 2025. We received a response from BIS closing the matter without further action. The voluntary self-disclosure with OFAC remains pending. We estimate that such potential violations represented less than one percent of our net revenue in each of our last three fiscal years. An unfavorable outcome of this investigation may include fines or penalties imposed in response to our voluntary disclosures. While we believe the amount of any fines or penalties would not be material to our financial condition and results of operation, we are unable to predict the outcome or the timing of resolution of these matters.

China Joint Ventures

On December 17, 2025, we completed the purchase of Fosun Industrial’s interests in Nature’s Sunshine Hong Kong Limited and Shanghai Nature’s Sunshine Health Products Co., Ltd., the Company's two joint ventures. Following the completion of the repurchases, the Company owned 100% of both joint ventures.

Tariffs

While we did not experience material impacts as a result of tariffs for the six months ended June 30, 2026 and 2025, we continue to monitor the additional pressure that tariff-related price increases may have on our business, including the price, availability and quality of raw materials and other ingredients. We expect that tariffs may adversely affect our costs in the remainder of 2026.

22

Table of Contents

RESULTS OF OPERATIONS

The following table summarizes our unaudited consolidated operating results from continuing operations in U.S. dollars and as a percentage of net sales for the three months ended June 30, 2026 and 2025 (dollar amounts in thousands):

[[GREPCENT_TABLE]]
[["Three Months Ended June 30,","","2026","","2025","","Change"],["","","Total dollars","","Percent of net sales","","Total dollars","","Percent of net sales","","Total dollars","","Percentage"],["Net sales","","$","116,985","","","100.0","%","","$","114,750","","","100.0","%","","$","2,235","","","1.9","%"],["Cost of sales","","30,811","","","26.3","","","32,451","","","28.3","","","(1,640)","","","(5.1)"],["Gross profit","","86,174","","","73.7","","","82,299","","","71.7","","","3,875","","","4.7"],["Volume incentives","","35,817","","","30.6","","","34,360","","","29.9","","","1,457","","","4.2"],["SG&A expenses","","44,876","","","38.4","","","43,665","","","38.1","","","1,211","","","2.8"],["Operating income","","5,481","","","4.7","","","4,274","","","3.7","","","1,207","","","28.2"],["Other income (expense), net","","(115)","","","(0.1)","","","3,270","","","2.8","","","(3,385)","","","(103.5)"],["Income before income taxes","","5,366","","","4.6","","","7,544","","","6.6","","","(2,178)","","","(28.9)"],["Provision for income taxes","","1,828","","","1.6","","","2,025","","","1.8","","","(197)","","","(9.7)"],["Net income","","$","3,538","","","3.0","%","","$","5,519","","","4.8","%","","$","(1,981)","","","(35.9)","%"]]
[[/GREPCENT_TABLE]]

The following table summarizes our unaudited consolidated operating results from continuing operations in U.S. dollars and as a percentage of net sales for the six months ended June 30, 2026 and 2025 (dollar amounts in thousands):

[[GREPCENT_TABLE]]
[["Six Months Ended June 30,","","2026","","2025","","Change"],["","","Total dollars","","Percent of net sales","","Total dollars","","Percent of net sales","","Total dollars","","Percentage"],["Net sales","","$","239,877","","","100.0","%","","$","227,998","","","100.0","%","","$","11,879","","","5.2","%"],["Cost of sales","","63,726","","","26.6","","","64,102","","","28.1","","","(376)","","","(0.6)"],["Gross profit","","176,151","","","73.4","","","163,896","","","71.9","","","12,255","","","7.5"],["Volume incentives","","72,710","","","30.3","","","69,204","","","30.4","","","3,506","","","5.1"],["SG&A expenses","","88,415","","","36.9","","","84,246","","","37.0","","","4,169","","","4.9"],["Operating income","","15,026","","","6.3","","","10,446","","","4.6","","","4,580","","","43.8"],["Other income (expense), net","","(1,505)","","","(0.6)","","","4,207","","","1.8","","","(5,712)","","","(135.8)"],["Income before income taxes","","13,521","","","5.6","","","14,653","","","6.4","","","(1,132)","","","(7.7)"],["Provision for income taxes","","4,865","","","2.0","","","4,250","","","1.9","","","615","","","14.5"],["Net income","","$","8,656","","","3.6","%","","$","10,403","","","4.6","%","","$","(1,747)","","","(16.8)","%"]]
[[/GREPCENT_TABLE]]

 Net Sales

International operations have provided, and are expected to continue to provide, a significant portion of our total net sales. As a result, total net sales will continue to be affected by fluctuations in the U.S. dollar against foreign currencies. In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, in addition to comparing the percent change in net sales from one period to another in U.S. dollars, we present net sales excluding the impact of foreign exchange fluctuations. We compare the percentage change in net sales from one period to another period by excluding the effects of foreign currency exchange as shown below. Net sales excluding the impact of foreign exchange fluctuations is not a U.S. GAAP financial measure and removes from net sales in U.S. dollars the impact of changes in exchange rates between the U.S. dollar and the functional currencies of our foreign subsidiaries, by translating the current period net sales into U.S. dollars using the same foreign currency exchange rates that were used to translate the net sales for the previous comparable period. We believe presenting the impact of foreign currency fluctuations is useful to investors because it allows a more meaningful comparison of net sales of our foreign operations from period to period. However, net sales excluding the impact of foreign currency fluctuations should not be considered in isolation or as an alternative to net sales in U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP. Throughout the last five years, foreign currency exchange rates have fluctuated significantly. See Item 3. Quantitative and Qualitative Disclosures about M

[Excerpt truncated for page length; source filing is linked above.]

## Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: https://www.sec.gov/Archives/edgar/data/275053/000162828026016540/natr-20251231.htm
Complete FY 2025 MD&A: /company/NATR/mda/fy2025/

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary.
Confidence: high
Filing date: 2026-03-10
Report date: 2025-12-31

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion highlights the principal factors that have affected our financial condition, results of operations, liquidity and capital resources for the periods described. This discussion should be read in conjunction with our consolidated financial statements and the related notes in Item 8, Part 2 of this report. This discussion contains forward-looking statements. Please see “Cautionary Note Regarding Forward-Looking Statements” for the risks, uncertainties and assumptions associated with these forward-looking statements.

22

Table of Contents

OVERVIEW

Our Business, Industry and Target Market

We are a global leader in manufacturing and marketing high-quality herbal and nutritional supplements. We are a Utah corporation with our principal place of business in Lehi, Utah, and sell our products directly to customers and to a sales force of independent consultants who resell our products to consumers.

Our independent consultants market and sell our products to customers and sponsor other independent consultants who also market our products to customers. Because a significant amount of revenue is generated through the sales of our independent consultants, our revenue can be impacted by the number and productivity of our independent consultants. We seek to motivate and provide incentives to our independent consultants by offering high quality products, product support, training seminars and financial incentives, among other considerations.

2025 Performance

In 2025, we experienced an increase in our consolidated net sales of 5.7 percent (or 5.3 percent in local currencies) compared to 2024. Asia net sales increased approximately 6.7 percent (or 6.4 percent in local currencies) compared to 2024. Europe net sales increased approximately 9.8 percent (or 7.8 percent in local currencies) compared to 2024. North America net sales increased approximately 3.4 percent (or 3.6 percent in local currencies) compared to 2024. Latin America and Other net sales decreased approximately 5.5 percent (or 4.2 percent in local currencies) compared to 2024. The strengthening of the U.S. dollar versus the local currencies, primarily in our Europe and Asia markets, resulted in an approximate 0.4 percent, or $1.8 million, increase of our net sales during the year ended December 31, 2025.

Cost of sales increased $2.7 million during 2025, compared to the same period in 2024, and as a percentage of net sales, were 27.6 percent and 28.5 percent for 2025 and 2024, respectively. The decrease in cost of sales percentage is primarily due to cost savings initiatives and market mix.

In absolute terms, selling, general and administrative expenses increased $14.4 million during 2025, and as a percentage of net sales, were 37.2 percent and 36.1 percent for 2025 and 2024, respectively. The increase was primarily related to the timing of compensation costs, incremental investment in digital marketing and consultant events, increased service fees due to China’s higher net sales, as well as other non-recurring expenses.

As an international business, we have significant sales and costs denominated in currencies other than the U.S. Dollar. We expect foreign markets with functional currencies other than the U.S. Dollar will continue to represent a substantial portion of our overall sales and related operating expenses. Accordingly, changes in foreign currency exchange rates could materially affect sales and costs or the comparability of sales and costs from period to period as a result of translating foreign markets' financial statements into our reporting currency.

Eastern Europe

On February 24, 2022, Russian forces launched significant military action against Ukraine. There continues to be sustained conflict and disruption in the region, which is expected to endure for the foreseeable future. Our consultants in the impacted regions continue to operate their independent businesses, albeit at a reduced level than prior to the start of the conflict. We expect that this will continue to impact our business for the foreseeable future. We will continue monitoring the social, political, regulatory and economic environment in Ukraine and Russia and will consider further actions as appropriate.

More broadly, there could be additional negative impacts to our net sales, earnings and cash flows should the situation escalate beyond its current scope, including, among other potential impacts, economic recessions in certain neighboring countries.

Net sales related to Eastern Europe for the years ended December 31, 2025 and 2024, were $60.0 million and $54.8 million, respectively. Operating income related to Eastern Europe for the years ended December 31, 2025 and 2024, were $4.7 million and $4.2 million, respectively. As of December 31, 2025, Eastern Europe had assets of $5.0 million, net of working capital reserves related to inventories.

In November 2024, we began an internal investigation regarding our past compliance with relevant U.S. trade controls and made an initial voluntary self-disclosure of apparent trade controls violations to the U.S. Department of Commerce's

23

Table of Contents

Bureau of Industry and Security (“BIS”). In addition, in April 2025, we filed an initial voluntary self-disclosure with the Office of Foreign Asset Control (“OFAC”) relating to the same internal investigation. Following our internal investigation, we filed final voluntary self-disclosures with BIS and OFAC on September 5, 2025. We estimate that such potential violations represented less than one percent of our net revenue in each of our last three fiscal years. An unfavorable outcome of this investigation may include fines or penalties imposed in response to our voluntary disclosures. While we believe the amount of any fines or penalties would not be material to our financial condition and results of operation we are unable to predict the outcome or the timing of resolution of these matters.

China Joint Ventures

On June 30, 2025, we entered into share purchase agreements with Fosun Industrial Co., Ltd. (“Fosun Industrial,” an affiliate of Fosun Pharma) to purchase Fosun Industrial’s interest in our two joint ventures, Nature’s Sunshine Hong Kong Limited and Shanghai Nature’s Sunshine Health Products Co., Ltd., for cash consideration in the amount of $3.9 million and $3.1 million, respectively.

On December 17, 2025, we completed the purchase of Fosun Industrial’s interests in both joint ventures. We acquired the interests in Nature’s Sunshine Hong Kong Limited for cash consideration of $3.1 million and acquired the interest in Shanghai Nature’s Sunshine Health Products for total consideration consisting of $2.9 million paid at closing and an additional $1.0 million payable on December 17, 2027.

Tariffs

While we did not experience material impacts as a result of tariffs in 2025, we continue to monitor the additional pressure that tariff-related price increases may have on our business, including the price, availability and quality of raw materials and other ingredients. We expect that tariffs will continue to adversely affect our costs in 2026.

Critical Accounting Policies and Estimates

Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and form the basis for the following discussion and analysis on critical accounting policies and estimates. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. On a regular basis, we evaluate our estimates and assumptions. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates and those differences could have a material effect on our financial position and results of operations. We have discussed the development, selection and disclosure of these estimates with the Board of Directors and our Audit Committee.

A summary of our significant accounting policies is provided in Note 1, “Nature of Operations and Significant Accounting Policies,” to our Consolidated Financial Statements, in Item 8, Part 2 of this report. We believe the critical accounting policies and estimates described below reflect our more significant estimates and assumptions used in the preparation of the consolidated financial statements. The impact and any associated risks on our business that are related to these policies are also discussed throughout this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” where such policies affect reported and expected financial results.

Revenue Recognition

Our revenue recognition practices are discussed in Note 2, “Revenue Recognition,” to our Consolidated Financial Statements, in Item 8, Part 2 of this report.

Inventories 

Inventories are adjusted to the lower of cost and net realizable value, using the first-in, first-out method. The components of inventory cost include raw materials, labor and overhead. To estimate any necessary adjustments, various assumptions are made in regard to excess or slow-moving inventories, non-conforming inventories, expiration dates, current and future product demand, production planning and market conditions. If future demand and market conditions are less favorable than our assumptions, additional inventory adjustments could be required.

24

Table of Contents

Incentive Trip Accrual

We accrue expenses associated with our direct sales program, which rewards independent consultants with paid attendance for incentive trips, including our conventions and meetings. Expenses associated with incentive trips are accrued over qualification periods as the trips are earned. We specifically analyze incentive trip accruals based on historical and current sales trends as well as contractual obligations when evaluating the adequacy of the incentive trip accrual. Actual results could generate liabilities in amounts greater or less than the amounts recorded. We had accrued incentive trip costs of approximately $4.8 million and $5.2 million at December 31, 2025 and 2024, respectively, which are included in accrued liabilities in the consolidated balance sheets.

Contingencies

We are involved in certain legal proceedings and disputes. When a loss is considered probable in connection with litigation or non-income tax contingencies and when such loss can be reasonably estimated with a range, we record our best estimate within the range related to the contingency. If there is no best estimate, we record the minimum of the range. As additional information becomes available, we assess the potential liability related to the contingency and revise the estimates. Revisions in estimates of the potential liabilities could materially affect our results of operations in the period of adjustment. Our contingencies are discussed in further detail in Note 11, “Commitments and Contingencies,” to our Consolidated Financial Statements, in Item 8, Part 2 of this report.

Income Taxes

Our income tax expense, deferred tax assets and liabilities and contingent reserves reflect our best assessment of estimated future taxes to be paid. We are subject to income taxes in both the United States and numerous foreign jurisdictions. Significant judgments and estimates are required in determining consolidated income tax expense.

Deferred income taxes arise from temporary differences between the tax and financial statement recognition of revenue and expense. In evaluating our ability to reco

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2025 MD&A: /company/NATR/mda/fy2025/
All MD&A years: /company/NATR/mda/


## MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

- [FY 2024 MD&A](/company/NATR/mda/fy2024/): filed 2025-03-11; accession 0001628280-25-012082 (https://www.sec.gov/Archives/edgar/data/275053/000162828025012082/natr-20241231.htm)
- [FY 2023 MD&A](/company/NATR/mda/fy2023/): filed 2024-03-12; accession 0001628280-24-010625 (https://www.sec.gov/Archives/edgar/data/275053/000162828024010625/natr-20231231.htm)
- [FY 2022 MD&A](/company/NATR/mda/fy2022/): filed 2023-03-16; accession 0000275053-23-000005 (https://www.sec.gov/Archives/edgar/data/275053/000027505323000005/natr-20221231.htm)
- [FY 2021 MD&A](/company/NATR/mda/fy2021/): filed 2022-03-08; accession 0000275053-22-000002 (https://www.sec.gov/Archives/edgar/data/275053/000027505322000002/natr-20211231.htm)


## FDA-approved drug applications

Applications listed under this company's exact-matched sponsor name. Approved applications only.

No resolved FDA applications were found for this company under the exact-unique, approved-only publish rule.

Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.

This list covers FDA applications whose listed sponsor name maps to this company by an exact-unique match; applications listed under sponsor names not mapped to this company (subsidiaries, name variants, joint ventures) are absent.


## Macro cross-references

Indicators mapped to this company's SIC classification (industry 2834 Pharmaceutical Preparations) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

- [INDPRO](/indicator/INDPRO/): Industrial Production: Total Index
- [TCU](/indicator/TCU/): Capacity Utilization: Total Index
- [PPIACO](/indicator/PPIACO/): Producer Price Index by Commodity: All Commodities
- [GDPC1](/indicator/GDPC1/): Real Gross Domestic Product
- [DGS10](/indicator/DGS10/): Market Yield on U.S. Treasury Securities at 10-Year Constant Maturity
- [FEDFUNDS](/indicator/FEDFUNDS/): Federal Funds Effective Rate
- [CES0500000003](/indicator/CES0500000003/): Average Hourly Earnings of All Employees, Total Private
- [PAYEMS](/indicator/PAYEMS/): All Employees, Total Nonfarm

Macro-to-micro threads including this sector: [Inflation (CPI / PCE / PPI)](/thread/inflation-cpi-pce-ppi/), [US labor market](/thread/us-labor-market/), [Growth & output](/thread/growth-output/), [Money & trade](/thread/money-trade/), [Government finances](/thread/government-finances/), [Sector employment](/thread/sector-employment/), [Industrial orders & inventories](/thread/industrial-orders/), [Trade & external](/thread/trade-external/).

All macro indicators: /indicators/


## For LLMs & downloads

Markdown twin: /company/NATR.md · JSON record: /company/NATR.json · verified financials: /company/NATR/financials.json / /company/NATR/financials.csv · machine TOC for the whole site: /llms.txt